ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
Selenium-Containing Type-I Organic Photosensitizers with Dual Reactive Oxygen Species of Superoxide and Hydroxyl Radicals as Switch-Hitter for Photodynamic Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 72 citations in OpenAlex.
- A Molecular Trimming Strategy for Hypoxia-Tolerant Photosensitizers With Enhanced cGAS-STING Activation.Angewandte Chemie (International ed. in English) · 2026Article
- Janus porphyrin-stabilized phase-transition theranostics for multimodal imaging-guided synergistic cancer therapy.Materials today. Bio · 2026Article
- Overcoming Tumor Hypoxia in Photodynamic Therapy: A Comprehensive Review of Oxygen-Delivery Carriers and Type I Photosensitizers.International journal of molecular sciences · 2026Review
- Activatable Silicon-Xanthene Photosensitizer for Photodynamic Therapy of Glioblastoma.Pharmaceutics · 2026Article
- Engineering Carbon Nitride Quantum Dots via Sulfur Doping for Controlled Reactive Oxygen Species Generation.Global challenges (Hoboken, NJ) · 2026Article
- "Dual lock-and-key" triggered and endoplasmic reticulum targeting nanophotosensitizers for activatable Type-I photodynamic and photothermal therapies.Chemical science · 2025Article
- Selenium-Substituted BOIMPY for Enhanced Photodynamic Therapy.ACS medicinal chemistry letters · 2025Article
- DFT-Based Elucidation and Evaluation of Selenium-Modified Tacrine Derivatives: Theoretical and Physicochemical Insights for Alzheimer's Disease Therapy.Molecules (Basel, Switzerland) · 2025Article
- Recent Advances in Nano-Drug Delivery Strategies for Chalcogen-Based Therapeutic Agents in Cancer Phototherapy.International journal of molecular sciences · 2025Review
- Selenium-containing nanoparticles and bone related disorders: from synthesis, bone metabolism to disease therapy.Frontiers in endocrinology · 2025Review
- Selenium Attenuates Radiation Colitis by Regulating cGAS-STING Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A Se Nanoparticle/MgFe-LDH Composite Nanosheet as a Multifunctional Platform for Osteosarcoma Eradication, Antibacterial and Bone Reconstruction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Efficient hydroxyl radical generation of an activatable phthalocyanine photosensitizer: oligomer higher than monomer and nanoaggregate.Chemical science · 2024Article
- pH/GSH dual responsive nanosystem for nitric oxide generation enhanced type I photodynamic therapy.Bioactive materials · 2024Article
- Galactosyl BODIPY-based nanoparticles as a type-I photosensitizer for HepG2 cell targeted photodynamic therapy.RSC advances · 2024Article
- Aryl-Modified Pentamethyl Cyanine Dyes at the C2' Position: A Tunable Platform for Activatable Photosensitizers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Selenium-Containing Type-I Organic Photosensitizers with Dual Reactive Oxygen Species of Superoxide and Hydroxyl Radicals as Switch-Hitter for Photodynamic Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Organic type-I photosensitizers (PSs) which produce aggressive reactive oxygen species (ROS) with less oxygen-dependent exhibit attractive curative effect for photodynamic therapy (PDT), as they adapt better to hypoxia microenvironment in tumors. However, the reported type-I PSs are limited and its exacted mechanism of oxygen dependence is still unclear. Herein, new selenium-containing type-I PSs of Se6 and Se5 with benzoselenadiazole acceptor has been designed and possessed aggregation-induced emission characteristic. Benefited from double heavy-atom-effect of selenium and bromine, Se6 shows a smaller energy gap (ΔE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.